test and of follow-up outcomes with Kaplan-Meier curves and logrank test.
Results: There were no differences between the two groups in terms of perioperative deaths, thromboses, or amputations. Follow-up was available for all the cases with a median duration of 26 months, without differences between the two groups. Estimated 4-year survival rates were 55.5% (standard error [SE] , 0.06) in group 1 and 71% (SE, 0.06) in group 2 (P ¼ .008; log-rank 6.9). At the same time interval, primary patency rates were 35% (SE, 0.06) in group 1 and 61.5% (SE, 0.06) in group 2 (P ¼ .002; log-rank 9.7); the corresponding figures in terms of secondary patency were 45.5% (SE, 0.055) and 64% (SE, 0.04; P ¼ .007; log-rank 7.2). Limb preservation rates at 48 years were 73% (SE, 0.05) in group 1 and 80% (SE, 0.04) in group 2 (P ¼ .3, log-rank 0.9), whereas the estimated 4-year amputation-free survival was 44.5% (SE, 0.05) in group 1 and 58% (SE, 0.05) in group 2 (P ¼ .03; log-rank 4.6).
Conclusions: ASV remains the material of choice in patients with CLI undergoing femorotibial bypass. However, in cases of unsuitable ASV, He-ePTFE is an effective alternative, providing long-term similar limb salvage rates in comparison with ASV in equivalent subgroups of patients Author Disclosures: P. Castelli: Nothing to disclose; W. Dorigo: Nothing to disclose; A. Fargion: Nothing to disclose; G. Piffaretti: Nothing to disclose; C. Pratesi: Nothing to disclose; R. Pulli: Nothing to disclose. Five-year primary and secondary cumulative graft patency, LS, and amputation-free survival (AFS) rates, and 6-month and 1-year wound healing rate which defined the duration from the bypass surgery to complete epithelialization as the healing time were evaluated and compared by the clinical stage as well as each clinical grades 0 to 3 of the WIfI classification.
PC140.
Results: Overall, the 5-year primary, secondary cumulative graft patency, AFS and LS rates were 65.1% and 82.7%, and 35.3% and 91.1%, respectively. The wound healing rate was 72.4% at 6 months and 94.7% at 1 year. The clinical stages significantly reflected the outcomes analyzed except LS (data not shown). Based on each grade comparison, AFS was significantly associated with wound: wound 0-1, 78.8% versus wound 2, 27.4% (P < .01), wound 3, 10.4% (P < .05), but not with ischemia or foot infection. Primary graft patency showed same tendency with AFS; wound 0-1, 87.5% versus wound 2, 47.5% and wound 3, 67.6% (P < .01 for each). Secondary graft patency was also associated with wound; wound 1, 94.7% versus wound 2, 69.3% (P ¼ .016), and wound 3, 88.2% (P ¼ .20). Regarding wound healing, the rate of wound 2 and wound 3 significantly delayed compared with wound 1; wound 1, 93.7% and 100% versus wound 2, 81.1% and 93.7% and wound 3, 50.1% and 89.6% at 6 months and 1 year after the bypass procedures (P < .01 for each). Intriguingly, neither ischemia nor foot infection were associated with the wound healing rate.
Conclusions: Surgical revascularization showed acceptable clinical results for patients with threatened limb attributed to pure isolated infrapopliteal lesions. WIfI classification was clinically important, but wound Objectives: A primary goal following lower limb amputation is to maximize patient quality of life (QoL) and satisfaction (SAT) with health. For those individuals that are candidates for prostheses, mobility (MOB) is also considered a primary goal. The role of the prosthesis in improving QoL and SAT is not well known. The purpose of this study was to examine the QoL, SAT, and MOB in a cross-sectional analysis of individuals with lower limb amputation owing to diabetes/vascular disease at various periods post amputation with and without a prosthesis.
Methods: Retrospective cross-sectional study of 761 patients with major lower limb amputation owing to vascular disease/diabetes (age,61.1 6 11.1 years; height, 174.6 6 10.6 cm; weight, 90.0 6 25.0 kg). Individuals were grouped according to whether they had a prosthesis and elapsed time since amputation (from 0 to 3 months up to 61-84 months). QoL and SAT were analyzed as separate elements of the validated Prosthesis Evaluation Questionnaire Well Being (PEQ-WB) in addition to the PEQ-WB composite score. MOB was calculated from the validated Prosthetic Limb Users Survey of Mobility (PLUS-M). Groups were compared through separate one-way analysis of variance with Fishers least squares difference post hoc tests. Study oversight was provided by the Western Institutional Review Board.
Results: Group sizes averaged 57 in the 6 prosthesis cohorts and 208 in the two no-prosthesis cohorts. Significant differences were found for QOL (F7,750 ¼ 3.558; P ¼ .001), SAT (F7,747 ¼ 3.223; P ¼ .002), and PEQ-WB score (F7,753 ¼ 3.297; P ¼ .002). Post hoc tests showed QOL, SAT and PEQ-WB scores were increased for patients with a prosthesis (P < .05), and that the scores for these individuals remained higher than scores reported by those without a prosthesis extending out as far as 61 to 84 months postamputation (Fig 1) . There were no significant differences for mobility among prosthesis users (F6, 368 ¼ 1.347; P ¼ .235; Fig 2) .
Conclusions: As time since amputation progresses without a prosthesis, QOL and SAT decrease for patients with amputation owing to vascular disease/diabetes. For individuals with a prosthesis, there is an initially elevated QOL and SAT, which then declines modestly and subsequently plateaus. Of note, QOL remained significantly greater than what is reported by those without a prosthesis at 4 to 6 months after amputation. Furthermore, mobility with a prosthesis is consistent throughout all examined periods, extending as far as 61 to 84 months after amputation with no reported decline across groups. Future work should investigate these effects through longitudinal analysis. Objectives: Several studies have demonstrated socioeconomic status affects surgical outcomes, however analyses in vascular surgery are limited. We sought to determine if the Distressed Communities Index (DCI), a composite socioeconomic score by zip code, could predict short and long-term outcomes after infrainguinal bypass.
Methods: Data on all VQI patients (N ¼ 2578) undergoing infrainguinal bypass (2011-2017) within a region of 17 centers were paired with the DCI scores. The metric was developed by the Economic Innovation Group and is normally distributed from 0 (no distress) to 100 (severe distress), accounting for unemployment, education level, poverty rate, median income, business growth, and housing vacancies. Patients were stratified by distressed (top DCI quartile) versus not for univariate analysis. Hierarchical regression assessed short-term outcomes and time-to-event analyses assessed long-term results.
Results: Infrainguinal bypass patients come from disproportionately distressed communities, with 29% of patients living within the top DCI quartile (P < .0001). These patients are younger, more likely to smoke, disproportionately African American, and have higher rates of medical comorbidities (all P < .05). While distressed communities had an equivalent rate of major adverse cardiac and cerebrovascular events (5% vs 4%; P ¼ .86), they have increased rates of major adverse limb events (MALE) at 13% vs 10% (P ¼ .03). This trend persists in the long term with higher overall rate of MALE (36% vs 30%; P ¼ .045; Fig) as well as the components of amputation (18% vs 14%; P ¼ .006) and thrombectomy (11% vs 7%; P ¼ .002). Revision rates were similar (18% vs 17%; P ¼ .50). Distressed  Fig 1. Long-term outcomes following dysvascular/diabetic amputation. 
